Ovarian Cancer

Ovarian cancer treatment has evolved with PARP inhibitor maintenance in BRCA-mutated or HRD-positive tumors, bevacizumab-containing regimens, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Ovarian Cancer

• Olaparib (Lynparza) — PARP Inhibitor
• Niraparib (Zejula) — PARP Inhibitor
• Rucaparib (Rubraca) — PARP Inhibitor
• Bevacizumab (Avastin) — Monoclonal Antibody
• Mirvetuximab soravtansine-gynx (Elahere) — Antibody-Drug Conjugate
• Carboplatin (Paraplatin) — Alkylating Agent
• Paclitaxel (Taxol) — Taxane
• Docetaxel (Taxotere) — Taxane
• Gemcitabine (Gemzar) — Antimetabolite
• Doxorubicin (Adriamycin) — Anthracycline
• Topotecan (Hycamtin) — Topoisomerase Inhibitor